SCHEMBL856589

SCHEMBL856589

Nc1ncc(-c2nc(N)ncc2-c2cnc3ccccc3c2)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 13/20 0.58
ADORA2A P29274 8/20 0.58
DHFR P00374 1/20 0.48
PDGFRB P09619 2/20 0.47
PDGFRA P16234 2/20 0.47
ALOX5AP P20292 1/20 0.47
FEN1 P39748 1/20 0.47
GFER P55789 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP2A6 P11509 1/20 0.45
BMPR1B O00238 1/20 0.45
PIK3C2G O75747 1/20 0.45
CDKL5 O76039 1/20 0.45
PIM1 P11309 1/20 0.45
TYK2 P29597 1/20 0.45
CLK2 P49760 1/20 0.45
DYRK1A Q13627 1/20 0.45
STK32B Q9NY57 1/20 0.45
PI4KB Q9UBF8 1/20 0.45
IRAK3 Q9Y616 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29818168 0.82 PDGFRB (0.62) DHFRPDGFRBPDGFRACYP2A6BMPR1B
SCHEMBL856588 0.82 BMPR1B (0.49) ADORA1ADORA2ADHFRPDGFRBPDGFRA
SCHEMBL17610545 0.77 ADORA2A (0.68) ADORA1ADORA2APDGFRBPDGFRACYP2A6
SCHEMBL2624503 0.76 PDGFRB (0.54) DHFRPDGFRBPDGFRAKMT2ACYP2A6
SCHEMBL17610492 0.74 IKBKB (0.49) ADORA1ADORA2APDGFRBPDGFRACYP2A6
SCHEMBL17610508 0.74 MGAM (0.50) ADORA1ADORA2APDGFRBPDGFRAALOX5AP
SCHEMBL2772360 0.74 PDGFRB (0.77) PDGFRBPDGFRACYP2A6
SCHEMBL32667946 0.74 PDGFRB (0.77) PDGFRBPDGFRACYP2A6
SCHEMBL4582424 0.73 ADORA1 (0.83) ADORA1ADORA2AGFERKMT2A
SCHEMBL6985344 0.72 POLB (0.57) ADORA1ADORA2APDGFRBPDGFRACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118087-B1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-03-28 EP disclosed